Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Transcriptional Regulation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDK8/CDK19 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDK8/CDK19 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CDK8/CDK19 Products |
| Gene Delivery | CDK8/CDK19 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CDK8/CDK19 Products |
| Benchmark Ab | Anti-CDK8/CDK19 (Sequence of Benchmark Inhibitor Control) Recombinant positive control. |
View CDK8/CDK19 Products |
| Validator | CDK8/CDK19 siRNA Set For knockdown verification. |
View CDK8/CDK19 Products |
| Related Target A | Cyclin C Essential binding partner for CDK8/19 kinase activity. |
View Cyclin C Products |
| Related Target B | MED12 Mediator complex subunit frequently mutated in tumors. |
View MED12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Activity Validation | Active CDK8/CycC and CDK19/CycC complexes available with >95% purity |
| Isoform Selectivity (CDK8 vs CDK19) | Homolog panel proteins strictly verified by mass spec for counter-screening |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CDK8/CDK19 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDK8/CDK19 therapeutics is intensifying, with major players focusing on small molecule kinase inhibitors and targeted protein degraders (PROTACs). As key regulators of the Mediator complex and transcriptional reprogramming, CDK8 and CDK19 are critical targets in overcoming resistance to current therapies in advanced solid tumors and hematological malignancies. The next wave of R&D is targeting highly selective dual inhibitors and combination therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Senex, Biotheryx | Breast Cancer, AML | Selectivity Assay (Need High-Purity Kinase Panels) |
| PROTAC / Degrader | Various Biotechs | Prostate Cancer, Solid Tumors | Degradation Assay (Need specific antibodies & cell lines) |
| Combination Therapy | Academic/Pharma | Therapy-Resistant Tumors | Pathway Validation (Need Mediator Complex Proteins) |